205 related articles for article (PubMed ID: 13679499)
1. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
Snanoudj R; Mamzer-Bruneel MF; Hermine O; Grunfeld JP; Chauveau D
Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
[No Abstract] [Full Text] [Related]
2. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
5. Primary amyloidosis of the kidney.
Shafique S; Wetmore J; Almehmi A
W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
[TBL] [Abstract][Full Text] [Related]
6. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.
Sanada S; Suzuki M; Shindo T; Suzuki S; Nakamichi T; Matsubara M; Maeda K
Nephrol Dial Transplant; 2008 Feb; 23(2):747-50. PubMed ID: 17989105
[No Abstract] [Full Text] [Related]
9. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
[TBL] [Abstract][Full Text] [Related]
11. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
Sanchorawala V; Seldin DC
Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Breems DA; Sonneveld P; de Man RA; Leebeek FW
Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
[TBL] [Abstract][Full Text] [Related]
13. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
[TBL] [Abstract][Full Text] [Related]
14. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
[TBL] [Abstract][Full Text] [Related]
15. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
16. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
17. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation.
Katoh N; Matsuda M; Yoshida T; Yazaki M; Morita H; Sakashita K; Ikeda S
Muscle Nerve; 2010 Jan; 41(1):138-43. PubMed ID: 19813189
[TBL] [Abstract][Full Text] [Related]
18. Nephrotic syndrome secondary to amyloidosis.
Kneipp S; Himmelstein SB
Nurse Pract; 2000 Jun; 25(6 Pt 1):78, 81, 85-6 passim. PubMed ID: 10884998
[TBL] [Abstract][Full Text] [Related]
19. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900
[TBL] [Abstract][Full Text] [Related]
20. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
